Synthace Ltd., the London, UK-based technology company behind the Antha operating system for biology, raised £7.3m ($9.6m) in Series A funding.
Backers included Cloud Capital, Amadeus Capital Partners and Eleven Two Capital and existing shareholders Sofinnova Partners, SOSV and Bioeconomy Capital.
The company intends to use the funds to expand the ecosystem of Antha adopters among biologists, lab instrumentation manufacturers, reagent and consumable suppliers, bio-design and analysis software developers and cloud provider.
Led by CEO Tim Fell, Synthace is developing Antha, a language and software platform specifically for biology researchers to make reproducible and scalable workflows that can be readily edited and shared, and automated on labs’ existing equipment, replacing current artisanal methods of development.
FinSMEs
19/09/2017